(Press-News.org) The European Society of Cardiology (ESC) has selected Roxana Mehran, MD, Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, as a winner of the organization’s top honor. Dr. Mehran was presented with the “ESC Gold Medal” during a special ceremony at the ESC Congress in Madrid on Friday, August 29.
The ESC Gold Medal recognizes exceptional scientists for their contributions to cardiovascular medicine and hopes this recognition will help them further inspire future generations.
“I am deeply humbled to receive the ESC Gold Medal, which represents not only a personal honor but also recognition of the collective work of my colleagues, collaborators, and mentors who have shaped my career,” says Dr. Mehran who is also the Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes at the Icahn School of Medicine at Mount Sinai. “This award underscores the importance of advancing cardiovascular science through innovation, collaboration, and mentorship, and I remain committed to ensuring that future generations of physicians and researchers continue to push the boundaries of what is possible in patient care.”
Dr. Mehran is an internationally renowned interventional cardiologist and clinical researcher in the field of cardiovascular disease. She is a globally respected for her work focused on designing and implementing randomized clinical trials and outcomes research projects, and publishing in high-impact academic publications. She has served as Principal Investigator for numerous global studies and developed important practice guidelines for treating patients with cardiovascular disease. She has focused on personalized medicine and developed individual risk scores for bleeding and acute kidney injury, participates regularly in developing clinical guidelines, and has authored more than 2,000 peer-reviewed articles.
Dr. Mehran is a member and 2025-2026 Vice President on the Board of Trustees of the American College of Cardiology (ACC). She is a founder and Chief Scientific Officer of the Cardiovascular Research Foundation (CRF).
Dr. Mehran leads the Lancet Commission on Women’s Cardiovascular Diseases, which has brought together leading researchers from around the world to identify and bridge gaps in scientific discovery, clinical trials, and care for women with cardiovascular disease. She was recently named Director of the Women’s Heart and Vascular Center at Mount Sinai Fuster Heart Hospital, spearheading a program that represents a collaboration across multiple disciplines designed to meet the specific needs of women’s cardiovascular health. In 2019, she founded Women as One, a not-for-profit organization dedicated to advancing opportunities for women in medicine, where she serves as Chair of the Board.
Dr. Mehran is a recipient of many prestigious awards, awards including the 2016 American College of Cardiology Bernadine Healy Leadership in Cardiovascular Disease Award, the 2018 Nanette Wenger Award from Women’s Heart for excellence in research and education, the 2019 Ellis Island Medal of Honor, and the 2019 European Society of Cardiology Silver Medal and Andreas Grüntzig Lecture Plaque. In 2022, she received The Terry Ann Krulwich Physician-Scientist Alumni Award at Mount Sinai; the Linda Joy Pollin Heart Health Leadership Award from Cedar Sinai Medical Center; the Doctor Honoris Causa Degree at Università della Svizzera Italiana; the Women in Cardiology Mentoring Award from the American Heart Association; and the Pulse-Setter Champion Award from The Cardiovascular Research Foundation. In 2023, she was honored with the Bahr Award of Excellence from the American College of Cardiology. In March 2024, she received the Jacobi Medallion, the top achievement award from the Icahn School of Medicine at Mount Sinai. In 2025, she was recognized with three of the field’s most prestigious honors: the American Heart Association Laennec Master Clinician Award, the Master of Masters Award at TCT Asia Pacific, and the European Society of Cardiology Gold Medal Award.
“We are tremendously proud of Dr. Roxana Mehran on receiving the European Society of Cardiology’s Gold Medal, one of the most prestigious honors in the field. This recognition reflects her pioneering contributions to interventional cardiology and clinical research, as well as her tireless dedication to improving cardiovascular outcomes worldwide,” explains Eric J. Nestler, MD, PhD, Interim Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President and Chief Scientific Officer of the Mount Sinai Health System. Dr. Mehran embodies the excellence, innovation, and global impact that define the Icahn School of Medicine, and we are honored to celebrate this well-deserved achievement with her.”
Mount Sinai Is a World Leader in Cardiology and Heart Surgery
Mount Sinai Fuster Heart Hospital at The Mount Sinai Hospital ranks No. 2 nationally for cardiology, heart, and vascular surgery, according to U.S. News & World Report®. It also ranks No. 1 in New York and No. 6 globally according to Newsweek’s “The World’s Best Specialized Hospitals.”
It is part of Mount Sinai Health System, which is New York City's largest academic medical system, encompassing seven hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 9,000 primary and specialty care physicians; 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 48 multidisciplinary research, educational, and clinical institutes. Hospitals within the Health System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report's® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
END
Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology
2025-08-29
ELSE PRESS RELEASES FROM THIS DATE:
World's first clinical trial showing lubiprostone aids kidney function
2025-08-29
Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive. Despite the severity of the condition, there are currently no drugs available that improve kidney function. A research group led by Tohoku University Graduate School of Medicine’s Professor Takaaki Abe has found a remarkable solution to treat patients with CKD by co-opting a drug typically used for constipation. This is the first time that this drug (lubiprostone) was shown to prevent the decline of renal function in patients with ...
Capturing language change through the genes
2025-08-29
Throughout human history, there have been many instances where two populations came into contact – especially in the past few thousand years because of large-scale migrations as a consequence of conquests, colonialization, and, more recently, globalization. During these encounters, not only did populations exchange genetic material, but also cultural elements.
When populations interact, they may borrow technologies, beliefs, practices, and also, crucially, aspects of language. With this, sounds, words or grammatical patterns can be exchanged ...
Public trust in elections increases with clear facts
2025-08-29
With control of Congress and a check on the Trump administration at issue in the 2026 midterm elections, the upcoming election cycle may again see claims of voter fraud.
But warning voters beforehand that there may be false claims about the election, and providing them with information on election security measures through "prebunking," can increase confidence in the results and decrease beliefs in voter fraud, according to a new study published in Science Advances.
"Prebunking is effective because it provides people with novel facts about how elections are ...
Thawing permafrost raised carbon dioxide levels after the last ice age
2025-08-29
Carbon dioxide levels in the atmosphere vary naturally between ice ages and interglacial periods. A new study by researchers at the University of Gothenburg shows that an unexpectedly large proportion of carbon dioxide emissions after the ice age may have come from thawing permafrost.
For a long time, it was the shifts between ice ages and interglacial periods that determined how much carbon dioxide was in the atmosphere. During ice ages, CO2 levels fell, only to rise by around 100 ppm (parts per million) during interglacial ...
New DNA test reveals plants’ hidden climate role
2025-08-29
Few of us ever think about what happens beneath our feet when we walk through a field of wheat or clover. We see the stalks, leaves, and flowers, but in practice we have no direct access to the roots.
Roots, however, are central. They anchor plants in the soil, supply them with water and nutrients, and contribute to carbon storage in the ground.
But because roots are hidden, researchers have for decades struggled to measure how much biomass lies below and how it is distributed among species.
“We have always known that roots are important, but we have lacked a precise tool to measure them. It’s a bit like studying marine ecosystems without ever being able to dive ...
Retinitis pigmentosa mouse models reflect pathobiology of human RP59
2025-08-29
BIRMINGHAM, Ala. – Retinitis pigmentosa retinal degeneration is caused by a family of hereditary mutations in nearly 100 genes that slowly lead to blindness over years or decades.
One of those genes encodes the enzyme DHDDS, part of the pathway that glycosylates proteins in higher cells. Retinitis pigmentosa from DHDDS mutations is called RP59. This is a recessive genetic disease, meaning mutations must be present on both copies of the DHDDS gene to cause disease.
To better understand and potentially treat RP59, Steven Pittler, Ph.D., and colleagues at the University of Alabama at Birmingham have created novel mouse models with mutations in the mouse gene for DHDDS.
Their first model, ...
Cell’s ‘antenna’ could be key to curing diseases
2025-08-29
Some might say it looks like a finger. Others might see a worm. Scientists in the field often liken it to an antenna. The technical name is primary cilium. This slender, microscopic appendage juts out from the surface of most cells in the human body — and yet for many years, it was completely missing from textbook illustrations.
Scientists began paying more attention to primary cilia around 2003. That’s when a scientist at Memorial Sloan Kettering Cancer Center (MSK), the late Kathryn Anderson, PhD, discovered that primary cilia play a hugely ...
Tiny ocean partnership between algae and bacteria reveals secrets of evolution
2025-08-29
The microscopic alliance between algae and bacteria offers rare, step-by-step snapshots of how bacteria lose genes and adapt to increasing host dependence. This is shown by a new study led by researchers from Stockholm University, in collaboration with the Swedish University of Agricultural Sciences and Linnaeus University, published in Current Biology.
In some of the most nutrient-poor waters of our oceans, tiny partnerships are hard at work keeping life going. These partnerships, called symbioses, are between microscopic algae known as diatoms and a specific bacteria called cyanobacteria that can take nitrogen ...
Scientists uncover cellular “toolkit” to reprogram immune cells for cancer therapy
2025-08-29
An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialised immune cells. The discovery, published in Immunity, could pave the way for more precise and personalised cancer immunotherapies.
About the study: basic research // peer-reviewed // in vitro // in vivo // mice //
The team has taken an important step toward harnessing the immune system to fight cancer. Their work describes how they identified a genetic toolkit that programs two powerful subtypes of dendritic cells – key sentinels of the immune system. Dendritic cells are a diverse group of immune cells that act as the body’s ...
Blocking protein control pathway slows rhabdomyosarcoma growth in mice
2025-08-29
“Together, these findings confirm that proteostasis inhibition can slow RMS growth and suggest that targeting compensatory network components might yield synergistic outcomes.”
BUFFALO, NY – August 29, 2025 – A new research paper was published in Volume 16 of Oncotarget on August 29, 2025, titled “In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.”
In this study led by first author Kristen Kwong and corresponding author Amit J. Sabnis from the Department of Pediatrics, Division of Oncology, ...